XTX Topco Ltd Takes Position in Kodiak Sciences Inc. $KOD

Key Points

• XTX Topco Ltd acquired 45,089 shares of Kodiak Sciences Inc., valued at approximately $126,000, increasing its ownership to 0.09% of the company.
• Several hedge funds have also increased their stakes in Kodiak Sciences, with Nantahala Capital Management LLC boosting its stake by 287.2% during the fourth quarter.
• Kodiak Sciences reported a quarterly loss of ($1.03) EPS, missing analysts' estimates, and has been given a new price target range of $7.00 to $15.00 by different research firms.

XTX Topco Ltd bought a new position in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 45,089 shares of the company's stock, valued at approximately $126,000. XTX Topco Ltd owned 0.09% of Kodiak Sciences at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in KOD. Vontobel Holding Ltd. acquired a new position in Kodiak Sciences in the first quarter worth approximately $28,000. Jump Financial LLC bought a new stake in shares of Kodiak Sciences during the 4th quarter worth $147,000. Public Employees Retirement System of Ohio grew its holdings in shares of Kodiak Sciences by 183.9% in the 4th quarter. Public Employees Retirement System of Ohio now owns 14,759 shares of the company's stock worth $147,000 after acquiring an additional 9,560 shares during the last quarter. MetLife Investment Management LLC acquired a new stake in shares of Kodiak Sciences during the fourth quarter worth $209,000. Finally, Aries Wealth Management purchased a new stake in shares of Kodiak Sciences during the first quarter valued at $70,000. 89.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KOD. JPMorgan Chase & Co. raised Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price target on the stock in a research note on Thursday, August 14th. HC Wainwright lifted their target price on shares of Kodiak Sciences from $3.00 to $5.00 and gave the stock a "neutral" rating in a research report on Monday. Finally, Barclays restated an "underweight" rating and set a $7.00 price target (up previously from $4.00) on shares of Kodiak Sciences in a report on Thursday.

Kodiak Sciences Stock Performance

Shares of NASDAQ KOD traded down $1.47 during mid-day trading on Tuesday, reaching $9.78. The company had a trading volume of 90,351 shares, compared to its average volume of 437,525. Kodiak Sciences Inc. has a twelve month low of $1.92 and a twelve month high of $11.60. The stock's 50 day moving average is $5.72 and its 200-day moving average is $4.44. The stock has a market capitalization of $516.69 million, a PE ratio of -2.57 and a beta of 2.41.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.02). On average, sell-side analysts anticipate that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.